{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,4]],"date-time":"2026-09-04T21:02:48Z","timestamp":1788555768801,"version":"build-2803163510"},"reference-count":35,"publisher":"MDPI AG","issue":"14","license":[{"start":{"date-parts":[[2026,7,9]],"date-time":"2026-07-09T00:00:00Z","timestamp":1783555200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JCM"],"abstract":"<jats:p>Incretin-based therapies have transformed the management of obesity and type 2 diabetes mellitus (T2DM). Established agents\u2014the glucagon-like peptide-1 receptor agonists (GLP-1 RAs) semaglutide and liraglutide, and the dual GIP\/GLP-1 receptor agonist tirzepatide\u2014are now widely used, while a diverse pipeline of multi-receptor agents is advancing through late-phase development. GLP-1 receptors are expressed in several oral and other craniofacial tissues, raising the question of how these drugs affect oral health. This narrative review (PubMed, EMBASE, Scopus, Web of Science, Cochrane Library, ClinicalTrials.gov; January 2010\u2013June 2026) integrates mechanistic studies, randomised controlled trials, pharmacovigilance data, society guidance, and the patient-facing phenomena increasingly raised in the dental chair. Preclinical and limited clinical evidence suggests that GLP-1 RAs may attenuate periodontal inflammation, while their effects on alveolar bone remain uncertain, reflecting both direct receptor and indirect metabolic influences. Concurrently, gastrointestinal adverse effects (nausea, vomiting, belching), reduced fluid intake, and possible salivary changes underlie a cluster of patient-reported complaints colloquially termed \u201cOzempic mouth\u201d, \u201cOzempic teeth\u201d, and \u201cOzempic breath\u201d, alongside the facial soft-tissue changes seen in \u201cOzempic face\u201d. Human oral-health-endpoint data remain scarce; much evidence is preclinical, indirect, or derived from case-level or pharmacovigilance reports. The oral cavity is nonetheless a plausible direct target of incretin pharmacotherapy and a practical monitoring site for tolerability. Dental practitioners should proactively manage the oral consequences of these agents, and validated oral health endpoints should be incorporated into future incretin trials.<\/jats:p>","DOI":"10.3390\/jcm15145358","type":"journal-article","created":{"date-parts":[[2026,7,9]],"date-time":"2026-07-09T10:16:22Z","timestamp":1783592182000},"page":"5358","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Oral Health Implications of GLP-1 Receptor Agonists and Other Incretin-Based Therapies"],"prefix":"10.3390","volume":"15","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5969-0865","authenticated-orcid":false,"given":"Julia","family":"Bijoch","sequence":"first","affiliation":[{"name":"Collegium Medicum\u2013Faculty of Medicine, WSB University, 41-300 Dabrowa Gornicza, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2026,7,9]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1016\/S0140-6736(19)31146-8","article-title":"Oral diseases: A global public health challenge","volume":"394","author":"Peres","year":"2019","journal-title":"Lancet"},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"989","DOI":"10.1056\/NEJMoa2032183","article-title":"Once-weekly semaglutide in adults with overweight or obesity","volume":"384","author":"Wilding","year":"2021","journal-title":"N. Engl. J. Med."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1056\/NEJMoa2206038","article-title":"Tirzepatide once weekly for the treatment of obesity","volume":"387","author":"Jastreboff","year":"2022","journal-title":"N. Engl. J. Med."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"2221","DOI":"10.1056\/NEJMoa2307563","article-title":"Semaglutide and cardiovascular outcomes in obesity without diabetes","volume":"389","author":"Lincoff","year":"2023","journal-title":"N. Engl. J. Med."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1016\/j.job.2015.06.002","article-title":"GLP-1R expression in the major salivary glands of rats","volume":"57","author":"Tsutsumi","year":"2015","journal-title":"J. Oral Biosci."},{"key":"ref_6","first-page":"e70465","article-title":"Expression of glucagon-like peptide-1 receptors in the submandibular gland of mice and its implications in type 2 diabetes","volume":"16","author":"Akakura","year":"2024","journal-title":"Cureus"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"e12997","DOI":"10.1111\/cpr.12997","article-title":"Stromal cell-derived factor-1\/Exendin-4 cotherapy facilitates the proliferation, migration and osteogenic differentiation of human periodontal ligament stem cells in vitro and promotes periodontal bone regeneration in vivo","volume":"54","author":"Liang","year":"2021","journal-title":"Cell Prolif."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"103310","DOI":"10.1016\/j.jdent.2020.103310","article-title":"Liraglutide regulates bone destruction and exhibits anti-inflammatory effects in periodontitis in vitro and in vivo","volume":"94","author":"Zhang","year":"2020","journal-title":"J. Dent."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1111\/j.1600-0757.2012.00457.x","article-title":"Risk factors for periodontal disease","volume":"62","author":"Genco","year":"2013","journal-title":"Periodonto 2000"},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1111\/jcpe.12803","article-title":"An update on the evidence for pathogenic mechanisms that may link periodontitis and diabetes","volume":"45","author":"Polak","year":"2018","journal-title":"J. Clin. Periodontol."},{"key":"ref_11","unstructured":"KFF (Kaiser Family Foundation) (2024). KFF Health Tracking Poll May 2024: The Public\u2019s Use and Views of GLP-1 Drugs, KFF. Available online: https:\/\/www.kff.org\/health-costs\/kff-health-tracking-poll-may-2024-the-publics-use-and-views-of-glp-1-drugs\/."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1111\/jre.13410","article-title":"Glucagon-like peptide 1 receptor agonists (GLP-1RAs) improve periodontal and peri-implant health in type 2 diabetes mellitus: A narrative review","volume":"60","author":"Ahmad","year":"2025","journal-title":"J. Periodontal Res."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"1765","DOI":"10.1007\/s00125-023-05906-7","article-title":"The expanding incretin universe: From basic biology to clinical translation","volume":"66","author":"Drucker","year":"2023","journal-title":"Diabetologia"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"209ra151","DOI":"10.1126\/scitranslmed.3007218","article-title":"Unimolecular dual incretins maximize metabolic benefits in rodents, monkeys, and humans","volume":"5","author":"Finan","year":"2013","journal-title":"Sci. Transl. Med."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"514","DOI":"10.1056\/NEJMoa2301972","article-title":"Triple-hormone-receptor agonist retatrutide for obesity\u2014A phase 2 trial","volume":"389","author":"Jastreboff","year":"2023","journal-title":"N. Engl. J. Med."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1056\/NEJMoa2502081","article-title":"Coadministered cagrilintide and semaglutide in adults with overweight or obesity","volume":"393","author":"Garvey","year":"2025","journal-title":"N. Engl. J. Med."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"648","DOI":"10.1056\/NEJMoa2502082","article-title":"Cagrilintide\u2013semaglutide in adults with overweight or obesity and type 2 diabetes","volume":"393","author":"Davies","year":"2025","journal-title":"N. Engl. J. Med."},{"key":"ref_18","first-page":"45","article-title":"Diagnosis and management of xerostomia and hyposalivation","volume":"11","author":"Villa","year":"2015","journal-title":"Ther. Clin. Risk Manag."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1038\/s41415-025-9345-4","article-title":"Glucagon-like peptide-1 receptor agonists: A review of the literature from a dental perspective","volume":"240","author":"McIntyre","year":"2026","journal-title":"Br. Dent. J."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"735","DOI":"10.1111\/anae.16306","article-title":"Glucagon-like peptide-1 receptor agonists: A narrative review of clinical pharmacology and implications for peri-operative practice","volume":"79","author":"Milder","year":"2024","journal-title":"Anaesthesia"},{"key":"ref_21","doi-asserted-by":"crossref","unstructured":"Bara\u0107, M., and Roganovi\u0107, J. (2025). GLP-1 receptor signaling and oral dysfunction: A narrative review on the mechanistic basis of semaglutide-related oral adverse effects. Biology, 14.","DOI":"10.3390\/biology14121650"},{"key":"ref_22","doi-asserted-by":"crossref","unstructured":"Kofman, K., and Ouanounou, A. (Can. J. Diabetes, 2026). Oral health considerations and dental management guidelines for semaglutide medications, Can. J. Diabetes, in press.","DOI":"10.1016\/j.jcjd.2026.03.008"},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"S135","DOI":"10.1111\/jcpe.12080","article-title":"Effect of periodontal disease on diabetes: Systematic review of epidemiologic observational evidence","volume":"40","author":"Borgnakke","year":"2013","journal-title":"J. Clin. Periodontol."},{"key":"ref_24","first-page":"CD004714","article-title":"Treatment of periodontitis for glycaemic control in people with diabetes mellitus","volume":"4","author":"Simpson","year":"2022","journal-title":"Cochrane Database Syst. Rev."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1038\/gene.2011.14","article-title":"State of the union between metabolism and the immune system in type 2 diabetes","volume":"12","author":"Nikolajczyk","year":"2011","journal-title":"Genes Immun."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1111\/jcpe.13189","article-title":"Periodontitis and cardiovascular diseases: Consensus report","volume":"47","author":"Sanz","year":"2020","journal-title":"J. Clin. Periodontol."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"2291","DOI":"10.1002\/lary.32061","article-title":"Otolaryngologic side effects of GLP-1 receptor agonists","volume":"135","author":"Khan","year":"2025","journal-title":"Laryngoscope"},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"e36730","DOI":"10.1097\/MD.0000000000036730","article-title":"Semaglutide-associated hyposalivation: A report of case series","volume":"102","author":"Mawardi","year":"2023","journal-title":"Medicine"},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"17","DOI":"10.36502\/2024\/droa.6189","article-title":"Possible adverse effects (AEs) of semaglutide (Ozempic) administration for the latest investigation","volume":"5","author":"Bando","year":"2024","journal-title":"Diabetes Res. Open Access"},{"key":"ref_30","doi-asserted-by":"crossref","unstructured":"Jeong, N., Chuang, L.-H., and Ho, Y. (2025). Periodontitis and GLP-1 pathways: A new frontier in oral-systemic health connections\u2014A scoping review. Front Clin. Diabetes Healthc., 6.","DOI":"10.3389\/fcdhc.2025.1679511"},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"e00277-17","DOI":"10.1128\/IAI.00277-17","article-title":"Degradation of incretins and modulation of blood glucose levels by periodontopathic bacterial dipeptidyl peptidase 4","volume":"85","author":"Nakasato","year":"2017","journal-title":"Infect. Immun."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"102624","DOI":"10.1016\/j.eclinm.2024.102624","article-title":"Once-weekly semaglutide versus placebo in adults with increased fracture risk: A randomised, double-blinded, two-centre, phase 2 trial","volume":"72","author":"Hansen","year":"2024","journal-title":"eClinicalMedicine"},{"key":"ref_33","unstructured":"American Society of Anesthesiologists (2023). Consensus-Based Guidance on Preoperative Management of Patients (Adults and Children) on Glucagon-like Peptide-1 (GLP-1) Receptor Agonists, ASA. Available online: https:\/\/www.asahq.org\/about-asa\/newsroom\/news-releases\/2023\/06\/american-society-of-anesthesiologists-consensus-based-guidance-on-preoperative."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"2083","DOI":"10.1016\/j.cgh.2024.10.003","article-title":"Multisociety Clinical Practice Guidance for the Safe Use of Glucagon-like Peptide-1 Receptor Agonists in the Perioperative Period","volume":"23","author":"Kindel","year":"2025","journal-title":"Clin. Gastroenterol. Hepatol."},{"key":"ref_35","unstructured":"American Dental Association (2025). Oral Health Topics: Dental Erosion, ADA Center for Scientific Information. Available online: https:\/\/www.ada.org\/resources\/ada-library\/oral-health-topics\/dental-erosion."}],"container-title":["Journal of Clinical Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2077-0383\/15\/14\/5358\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,9]],"date-time":"2026-07-09T10:36:26Z","timestamp":1783593386000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2077-0383\/15\/14\/5358"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,9]]},"references-count":35,"journal-issue":{"issue":"14","published-online":{"date-parts":[[2026,7]]}},"alternative-id":["jcm15145358"],"URL":"https:\/\/doi.org\/10.3390\/jcm15145358","relation":{},"ISSN":["2077-0383"],"issn-type":[{"value":"2077-0383","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,9]]}}}